In today’s post, we provide the questions that were sent in and asked during the live session of our Questions and Experts session held on October 3, 2023. In this session, Surgical Oncologist Dr. Mark Basik answers your questions about clinical trials. In the parentheses, you’ll find the timestamp of where to find the question in the on-demand video.

As with most other events planned for this year, the ASCO 2020 Conference was rescheduled as a virtual event, originally set to be held in Chicago from May 29^th to 31^st. The American Society of Clinical Oncology (ASCO) Conference is a key research conference that brings together clinicians, researchers, and patient advocates from around the world. The conference included over 5,000 abstracts, posters, slides and videos, a day of video broadcasts and around 147 virtual exhibits. While we weren’t able to come together in person this year, ASCO successfully hosted a virtual conference that shared an incredible amount of research that’s relevant to breast cancer patients. Below are some of the highlights.

I’m from Ottawa. I was diagnosed de novo in March 2011 with metastatic breast cancer and metastasis to the bone. I am 53 years old. I am a mother, daughter, sister, artist, lesbian, atheist, and gardener.

I learned about “timely and equitable access” to oncology drugs at the Canadian Breast Cancer Network's metastatic breast cancer advocacy training in 2013. I was the first in Canada prescribed Perjeta, days after Health Canada approved the drug. My oncologist shared exciting trial results about dual blockade (using two drugs simultaneously against breast cancer). The trastuzumab emtansine (TDM-1) trial had closed days earlier. Another combo was available but it was “back pocket.” The caveat was that it wasn’t funded but my extended health insurance benefits agreed to pay. On route to my first infusion, I penned a sign: BELIEVE. We did. I had dozens of liver and lymph mets and my liver was failing. After two rounds, I had normal liver enzymes and after three, normal tumour markers.